Small Financial Incentives to Promote Smoking Cessation (Prevail II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02737566|
Recruitment Status : Recruiting
First Posted : April 14, 2016
Last Update Posted : August 6, 2019
|Condition or disease||Intervention/treatment||Phase|
|Smoking Cessation||Behavioral: Standard Care + Financial Incentives Other: Standard Care||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||320 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Small Financial Incentives to Promote Smoking Cessation in Safety Net Hospital Patients|
|Actual Study Start Date :||January 30, 2017|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||January 2020|
Experimental: Standard Care + Financial Incentives
Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
Behavioral: Standard Care + Financial Incentives
Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
Active Comparator: Standard Care
Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
Other: Standard Care
Tobacco cessation counseling plus pharmacotherapy.
- Biochemically-verified smoking cessation [ Time Frame: 26 weeks post-quit ]The primary outcome measure is biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit.
- Biochemically-verified smoking cessation [ Time Frame: 12 weeks post-quit ]The secondary outcome measure is biochemically-verified 7-day point prevalence abstinence at 12 weeks post-quit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02737566
|Contact: Joseph Waring||(405) 271-8001 ext firstname.lastname@example.org|
|Contact: Darla E. Kendzor, Ph.D.||(405) 271-8001 ext 50478||Darla-Kendzor@ouhsc.edu|
|United States, Oklahoma|
|Oklahoma Tobacco Research Center||Recruiting|
|Oklahoma City, Oklahoma, United States, 73104|
|Contact: Joseph Waring 405-271-8001 ext 31153 email@example.com|
|Contact: Darla Kendzor, Ph.D. (405) 271-8001 ext 50478 Darla-Kendzor@ouhsc.edu|
|Principal Investigator: Darla Kendzor, Ph.D.|
|Sub-Investigator: Michael Businelle, Ph.D.|
|Principal Investigator:||Darla E. Kendzor, Ph.D.||University of Oklahoma|